Pharvaris N.V. (NASDAQ:PHVS) Sees Large Decrease in Short Interest

Pharvaris N.V. (NASDAQ:PHVS) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totaling 600,645 shares, a decrease of 42.9% from the April 30th total of 1,051,478 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average daily volume of 463,899 shares, the days-to-cover ratio is currently 1.3 days.

Insider Activity

In related news, Director Elisabeth Bjork sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $29.32, for a total transaction of $293,200.00. Following the completion of the sale, the director directly owned 15,167 shares in the company, valued at $444,696.44. This represents a 39.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Viviane Monges sold 9,667 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.29, for a total value of $292,813.43. Following the sale, the director owned 5,500 shares of the company’s stock, valued at $166,595. This trade represents a 63.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 209,948 shares of company stock worth $6,268,141 over the last ninety days. 11.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new position in shares of Pharvaris in the third quarter valued at about $1,943,000. Patient Square Capital LP grew its holdings in Pharvaris by 41.4% during the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after acquiring an additional 101,098 shares during the period. Integral Health Asset Management LLC acquired a new stake in Pharvaris during the third quarter worth about $4,990,000. JPMorgan Chase & Co. boosted its position in Pharvaris by 710.4% during the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after purchasing an additional 23,743 shares in the last quarter. Finally, Boothbay Fund Management LLC boosted its position in Pharvaris by 735.1% during the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after purchasing an additional 118,994 shares in the last quarter.

Pharvaris Trading Up 3.9%

Shares of PHVS stock traded up $1.16 during mid-day trading on Thursday, reaching $31.30. The stock had a trading volume of 64,868 shares, compared to its average volume of 231,653. The business’s fifty day moving average is $29.01 and its 200-day moving average is $27.22. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -9.84 and a beta of -2.35. Pharvaris has a 1-year low of $15.91 and a 1-year high of $33.33.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, analysts forecast that Pharvaris will post -3.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PHVS has been the subject of a number of analyst reports. Wedbush upped their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada decreased their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Wolfe Research started coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Citizens Jmp decreased their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Finally, Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.